Biotech’s coming of age

- Biotech is back, but the ledger has changed. Nature Biotechnology notes that while capital returns, it arrives with caution, shaped by China’s ascent and the relentless hum of AI. This isn’t just about new drugs; it’s about digital infrastructure in medicine. AI is reshaping trial design, turning patient data into predictive models rather than just records. The sector’s contours are being redrawn by algorithms, not just molecules. It’s a quiet revolution: med-tech meets machine learning, where diagnostics are sharper and trials are smarter. No panic, just progress. The odd charm lies in the precision—less guesswork, more data. Biotech’s coming of age is defined by this hybrid intelligence.